Sanofi-aventis' Multaq receives US FDA nod to treat patients with atrial fibrillation or atrial flutter | 3 Jul 09, 05:48

Home | Support

Headline News:

FDA

Drug Testing

Internet Safety

Sanofi-aventis' Multaq receives US FDA nod to treat patients with atrial fibrillation or atrial flutter

3 Jul 09, 05:48

Sanofi-aventis announced that the US Food and Drug Administration (FDA) has approved Multaq (dronedarone) 400 mg tablets.